UG

Shares of United-Guardian, Inc. UG have declined 0.9% since reporting second-quarter 2026 results, underperforming the S&P 500 index’s 0.2% return. Over the past month, the stock has fallen 1.1%, while the S&P 500 has advanced 1.5%. United-Guardian reported second-quarter net sales of $3.11 million, up 10% from $2.84 million a year earlier. Net income increased 16% to $728,579 from $626,826, while earnings per share rose 14.3% to 16 cents from 14 cents. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote Cosmetic ingredient sales increased 44% year over year in the second quarter, substantially outpacing the companywide sales advance. Pharmaceutical sales grew 1%, with Renacidin, United-Guardian’s most important pharmaceutical product, identified as the primary growth driver within that category. The release did not provide dollar sales by product line or disclose quarterly growth rates for medical lubricants or sexual wellness ingredients. For the six months ended June 30, net sales rose 12% year over year to $5.98 million from $5.32 million. Net income advanced 30% to $1.55 million from $1.19 million, and earnings per share increased 30.8% to 34 cents from 26 cents. First-half cosmetic ingredient sales climbed 34%, while pharmaceutical sales increased 11%. President Donna Vigilante said that sales and earnings increased in the second quarter and first half. She attributed the cosmetic ingredient improvement primarily to increased purchases by Ashland Specialty Ingredients, United-Guardian’s largest cosmetic distributor. Ashland had carried higher-than-normal inventory during 2025, but those levels were subsequently reduced, allowing regular purchasing levels to resume in the first half of 2026. Management’s growth plan remains centered on expanding promotional efforts and increasing awareness of Renacidin among physicians and care providers. The company also intends to raise awareness of its “natural” products and grow its medical lubricant business. The comments set strategic priorities but did not quantify expected sales, earnings or spending associated with those initiatives. Second-quarter cost of sales increased 16.5% to $1.56 million from $1.34 million, faster than the 10% sales increase. Gross profit consequently rose only 3.2% to $1.55 million, while the gross margin narrowed to 49.7% from 52.8%. Operating expenses declined 3.9% to $667,282, but research and development expenses increased 15.3% to $124,395. Total costs and expenses rose 9.9% to $2.35 million, leaving operating income 8.4% higher at $754,125. Total other income increased 71.8% to $163,480 from $95,149, helping pretax income rise 16.1% to $917,605. Investment income was nearly unchanged at $70,445 compared with $70,573. Net gains on marketable securities increased to $48,365 from $24,576. The quarter also included $36,360 of settlement income and an $8,310 gain on an asset sale, neither of which appeared in the prior-year quarter. The income tax provision rose 15.4% to $189,026. The first-half figures show a similar split between operating and non-operating growth. Cost of sales rose 22.2% to $3.01 million, limiting gross-profit growth to 4% and reducing the gross margin to 49.7% from 53.7%. Operating income increased 6.9% to $1.4 million. By contrast, total other income nearly tripled to $554,169 from $192,186, principally reflecting $339,493 of settlement income, alongside $66,107 in marketable-securities gains and the $8,310 asset-sale gain. As a result, first-half pretax income rose 30.2% to $1.95 million, broadly matching the 30% increase in net income, while the tax provision grew 29.7% to $403,262. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United-Guardian, Inc. (UG): Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

HAUPPAUGE, N.Y., Aug. 07, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from $2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share) to $728,579 ($0.16 per share). Net sales for the six-month period ended June 30th increased by 12% from $5,319,352 in 2025 to $5,980,489 in 2026, and net income increased by 30% from $1,187,721 ($0.26 per share) to $1,547,481 ($0.34 per share). Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that sales and earnings increased in both the second quarter and first half of 2026. Sales of our cosmetic ingredients and pharmaceutical products increased during both periods compared with the same periods in 2025. Cosmetic ingredient sales increased by 44% in the second quarter and 34% in the first half of 2026 compared with the same periods in 2025. The growth in cosmetic ingredient sales was primarily attributable to increased purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. ASI had experienced higher-than-normal inventory levels in 2025, which have since been reduced, resulting in the resumption of regular purchasing levels in the first half of 2026. Pharmaceutical sales increased by 1% in the second quarter and 11% in the first half of 2026 compared with the same periods in 2025, with Renacidin®, our most important pharmaceutical product, serving as the primary driver of growth.” “As we move through 2026, we remain focused on our growth plan, which includes expanding promotional efforts and increasing market awareness for Renacidin, particularly among physicians and care providers; increasing awareness of our “natural” products; and growing our medical lubricant business.” United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Shares of United-Guardian, Inc. UG have gained 2.3% since reporting results for the first quarter of 2026, outperforming the S&P 500 index’s 0.8% return. Over the past month, the stock has advanced 7.7% compared with the S&P 500’s 5% rise, reflecting stronger investor sentiment following the company’s quarterly update. United-Guardian reported first-quarter 2026 net sales of $2.87 million, up 15.8% from $2.48 million in the year-ago quarter. Net income climbed 46% year over year to $818,902 from $560,895, while earnings per share increased to 18 cents from 12 cents. Income from operations rose 5.2% to $642,449 despite higher operating costs. Total other income surged to $390,689 from $97,037 a year earlier, aided by settlement income tied to production disruptions involving a contract manufacturer. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote The company attributed the quarter’s stronger performance primarily to higher sales in its pharmaceutical and cosmetic ingredients businesses. Pharmaceutical sales increased 24% year over year, driven largely by stronger demand for Renacidin, United-Guardian’s key pharmaceutical product. Management said efforts to increase market penetration and expand outreach for Renacidin contributed to the improvement. Cosmetic ingredient sales rose 21% from the prior-year period. The increase was mainly due to larger purchases from Ashland Specialty Ingredients (“ASI”), the company’s largest distributor of cosmetic ingredients. ASI purchases jumped 45% year over year after inventory reductions in 2025 had weighed on ordering activity. Domestic sales rose to $2.37 million from $1.76 million in the prior-year quarter, while export sales declined to about $499,000 from $725,000. As a result, domestic business represented about 83% of the total sales compared with roughly 71% a year earlier. Management also noted that the company continued expanding beyond its “natural” product portfolio during the quarter, with increased marketing efforts focused on pharmaceutical products and cosmetic preservatives. Cost of sales increased 28.9% year over year to $1.45 million, outpacing revenue growth due to a shift in product mix. Operating expenses rose 5.4% to $666,963, reflecting higher insurance and payroll-related costs. Research and development expenses were relatively stable at $115,021 compared with $114,394 in the prior-year quarter. Despite higher costs, profitability improved meaningfully because of stronger sales and additional income items. Gross profit increased to $1.42 million from $1.36 million in the year-earlier quarter. A major contributor to earnings growth was $303,133 in settlement income recognized during the quarter. The payment was related to an unexpected shutdown at the facility of the company’s contract manufacturer for Renacidin in late 2023, which had previously resulted in lost sales. Investment income declined to $69,814 from $84,687 because of lower average balances in U.S. Treasury holdings during the quarter. Net gains on marketable securities increased modestly to $17,742 from $12,350. United-Guardian ended the quarter with cash and cash equivalents of approximately $756,000, down from $1.25 million as of Dec. 31, 2025. The decline primarily reflected increased purchases of marketable securities. Marketable securities rose sharply to $7.4 million from $5.3 million at the end of 2025. The company continued to maintain a debt-free balance sheet and reported working capital of $9.35 million as of March 31, 2026. Cash provided by operating activities totaled $840,576 in the quarter compared with $722,968 in the prior-year period, supported by higher earnings. President Donna Vigilante said the company was encouraged by the first-quarter improvement in both sales and earnings. She highlighted the recovery in purchasing activity from ASI and stronger Renacidin demand as important contributors to the quarter’s performance. Management also expressed optimism about continued growth in 2026. The company cited resumed regular purchasing patterns from ASI, new distribution agreements and ongoing efforts to expand Renacidin outreach and market penetration as positive factors for future sales trends. While the company did not issue formal quantitative guidance, management’s commentary suggested expectations for continued revenue improvement during the remainder of the year. During the quarter, United-Guardian continued initiatives aimed at broadening its product portfolio and strengthening distribution relationships. The company also maintained its quarterly dividend program. In January 2026, the board declared a cash dividend of 35 cents per share, which was paid out in February. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United-Guardian, Inc. (UG): Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share). Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by 24% in the first quarter of 2026, driven primarily by increased demand for Renacidin®, our most important pharmaceutical product. Sales of our cosmetic ingredients increased by 21%, with the increase primarily attributable to an increase in purchases by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). ASI’s purchases increased by 45% in the first quarter of 2026 compared with the first quarter of 2025. The lower purchases by ASI in 2025 were primarily the result of ASI carrying excess inventory, which suppressed its purchase levels. This excess inventory has now been worked off, and they have resumed regular purchase levels.” “In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.” “With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.” United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Shares of United-Guardian, Inc. UG have gained 6.3% since the company reported its earnings for 2025, outperforming the broader market as the S&P 500 declined 1.7% over the same period. Over the past month, the stock has risen 2.3%, again showing relative strength compared with the S&P 500’s steeper 7.6% decline. United-Guardian reported weaker financial results for 2025 compared with 2024, with both revenues and earnings declining. Net sales fell 13% year over year to $10.55 million from $12.18 million. Net income dropped sharply to $2.11 million from $3.25 million in the prior year, representing a decline of roughly 35%. Earnings per share followed a similar trajectory, decreasing to 46 cents from 71 cents. Operating income also contracted significantly, falling to $2.24 million from $3.65 million in 2024, reflecting lower sales volumes and a modest rise in operating expenses. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote A closer look at cost structures shows some mixed trends. Total costs and expenses declined slightly to $8.30 million from $8.54 million, primarily due to a reduction in cost of sales, which fell to $5.40 million from $5.72 million. However, operating expenses increased modestly to $2.43 million, while research and development spending rose slightly to $463,644 from $456,779. Despite cost controls in certain areas, the reduction in revenue outweighed these improvements, leading to a notable contraction in profitability. On the balance sheet side, total assets decreased to $13.11 million at year-end 2025 from $13.80 million in 2024. Stockholders’ equity also declined to $11.23 million from $11.88 million, reflecting the lower earnings base. Meanwhile, current liabilities decreased to $1.67 million from $1.91 million, indicating some improvement in short-term obligations. Management attributed the year-over-year decline primarily to weakness in the company’s cosmetic ingredients segment. President Donna Vigilante highlighted that excess inventory held by the company’s largest distributor, Ashland Specialty Ingredients, led to reduced order volumes throughout the year. Additionally, global demand softness — particularly in China — further pressured sales, compounded by increased competition from local Asian producers and the impact of tariffs. Despite these headwinds, management pointed to several positive developments. Sales of pharmaceutical products increased 15% year over year, while medical lubricant sales rose 4%. The growth in pharmaceuticals was driven by higher sales to national drug wholesalers and reduced Medicare rebates. Meanwhile, increased demand from contract manufacturing customers in China supported gains in the medical lubricants segment. Management also emphasized strategic initiatives aimed at improving future performance. These include efforts to regain market share in China through competitive pricing and product differentiation, as well as expanding into new markets less affected by cost pressures. The primary factor behind the decline in headline financial metrics was the downturn in cosmetic ingredient sales, historically a key revenue driver for the company. Distributor inventory overhang significantly reduced order flow, highlighting a dependency risk in the distribution channel. At the same time, macroeconomic and geopolitical factors — including tariffs and regional competition — further constrained demand. Conversely, diversification across product lines provided some cushion. Growth in pharmaceuticals and medical lubricants partially offset declines in cosmetics, demonstrating the importance of the company’s multi-segment portfolio. However, these gains were insufficient to fully counterbalance the broader revenue contraction. Investment income also declined year over year, falling to $365,308 from $434,679, contributing to the overall drop in net income. Management expressed optimism about future growth prospects. Key initiatives include a new marketing strategy for Renacidin to increase domestic awareness and secure additional drug formulary placements. The company has already received approval from two major pharmacy benefit managers, which is expected to improve patient access and support long-term sales growth. Additionally, new marketing and distribution agreements for cosmetic ingredients signed in 2025 are expected to help rebuild momentum in that segment. Management indicated confidence that these efforts, combined with ongoing collaboration with international distributors, will lead to improved sales performance in the coming years. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United-Guardian, Inc. (UG): Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025. Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of our cosmetic ingredients. One of the issues we faced was excess inventory held by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). The inventory overstock led to reduced order quantities from ASI throughout the year. The situation was further impacted by decreased global demand for our products, particularly in China, where heightened competition from local Asian producers, and the impact of global tariffs, negatively impacted sales. In response to these challenges, we have been collaborating closely with our distributor in China to regain lost market share, offering competitive pricing where feasible, differentiating our products from the competition, and exploring new markets where cost pressures are less pronounced.” “On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by 15% and by 4%, respectively. The increase in medical lubricants was driven by greater demand from two of our large contract manufacturer customers in China. The increase in pharmaceutical sales resulted from an increase in sales to all three of our national drug wholesalers, combined with a decrease in Medicare rebates. In 2025 we initiated a new marketing strategy to expand the domestic sales of Renacidin® by increasing awareness of Renacidin and seeking its inclusion on additional drug formularies. I am happy to report that we recently received approval from two major pharmacy benefit managers. We believe that having Renacidin available on additional drug formularies will enhance patient access and will support the product’s long-term commercial growth. We are optimistic that this initiative, along with the new marketing and distribution agreements we entered into in 2025 for our cosmetic ingredients, will result in increased sales in the coming years.” United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

HAUPPAUGE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2025. Sales for the nine-month period ended September 30th decreased from $9,705,262 in 2024 to $7,583,613 in 2025 and net income decreased from $2,747,151 ($0.60 per share) to $1,456,162 ($0.32 per share). Third quarter sales decreased from $3,060,113 in 2024 to $2,264,261 in 2025 and net income decreased from $865,484 ($0.19 per share) to $268,441 ($0.06 per share). Donna Vigilante, President of United-Guardian, stated, “While sales of our pharmaceutical and medical products both increased during the first nine-months of 2025 compared with the same period in 2024 (increasing by 10% and 6%, respectively), we did experience a decrease in sales of our cosmetic ingredients in this year’s third quarter compared with 2024. That decrease was attributable primarily to reduced purchases of our cosmetic ingredients by Ashland Specialty Ingredients (“ASI”), our largest marketing partner, which has been dealing with difficult tariff and geopolitical concerns in Asia that have caused some customers to move towards lower cost local products. This has resulted in ASI having to work down excess inventory, which has caused a decrease in their orders this year. This is consistent with recent reports that indicated that sales and earnings of U.S. chemical companies in the third quarter were depressed mainly due to weak China demand, continued destocking, and tariffs. ASI has indicated to us that it is confident that it will be able to regain market share by offering more competitive pricing going forward.” “On a positive note we have made progress with our project to increase sales of Renacidin®, our most important pharmaceutical product, by working with an outside pharmaceutical consultant to have Renacidin included on additional drug formularies. We are excited about the potential this project has to significantly increase sales of Renacidin over the coming years. We are hopeful that this project, along with the new marketing agreements we have negotiated recently for some of our new personal care products, will give us an excellent opportunity to increase our revenue in the coming years. United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission. Financial Results for the Three and Nine Months Ended September 30, 2025 and 2024 STATEMENTS OF INCOME (unaudited)

Shares of United-Guardian UG have risen 1.5% since reporting second-quarter 2025 results, trailing the S&P 500 index’s 1.8% growth. However, over the past month, the stock has fallen 0.6%, underperforming the broader index’s 3.2% advance. This relative weakness over the month contrasts with its modest post-earnings uptick. For the three months ended June 30, 2025, United-Guardian posted net sales of $2.84 million, down 16.3% from $3.39 million a year earlier. Net income fell 34.5% year over year to $626,826, or 14 cents per share, from $956,225, or 21 cents per share. On a six-month basis, net sales declined 20% to $5.32 million from $6.65 million in the prior-year period, while net income slid 36.9% to $1.19 million, or 26 cents per share, from $1.88 million, or 41 cents per share. United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote Cost of sales as a percentage of net sales increased to 47% in the second quarter of 2025 from 46% in the year-ago quarter. Operating expenses rose 15.1% to $694,050 in the quarter, driven by higher marketing and selling costs. Research and development (R&D) expenses were relatively stable, slipping 3.4% to $107,868. Investment income for the quarter totaled $70,573, down from $100,007 in the same period of 2024, while the company booked a $24,576 net gain on marketable securities against a $9,501 loss a year ago. Sales performance varied significantly by product category. For the first half of 2025, sales of pharmaceuticals grew 11%, and medical lubricants rose 12% from the prior-year period. However, cosmetic ingredient sales dropped sharply due to reduced orders from the company’s largest distributor, Ashland Specialty Ingredients (“ASI”), which faced an inventory overstock, led by softer demand in Asia. Management indicated that efforts are underway to resolve the overstock and recover sales momentum in the second half of the year. President Donna Vigilante noted that the pharmaceutical and medical lubricant categories provided a measure of resilience in an otherwise weaker sales environment. The company is pursuing a strategic initiative to have Renacidin, its most important pharmaceutical product, added to additional drug formularies, a move expected to meaningfully boost sales in the coming years. Management acknowledged the cosmetic segment’s weakness but expressed optimism that resolving ASI’s inventory issue would restore growth. The year-over-year revenue decline was primarily linked to weakness in cosmetic ingredient sales, which outweighed gains in pharmaceuticals and medical lubricants. The cosmetic category’s softness was concentrated in sales to Asia, especially China, where subdued demand created excess inventory at ASI. On the expense side, higher marketing and selling costs contributed to rising operating expenses, pressuring margins alongside the lower sales base. Additionally, investment income dropped as market conditions delivered smaller returns on the company’s portfolio compared to 2024. The company’s cost-of-sales ratio remained relatively steady, suggesting pricing and production costs were not significantly disrupted despite revenue pressures. Gains on marketable securities provided a modest offset to lower investment income in the quarter. Management expects a rebound in cosmetic ingredient sales in the second half, contingent on the resolution of ASI’s inventory overhang. The company also anticipates potential long-term upside from expanding Renacidin’s formulary inclusion, though this is dependent on the successful execution of its current initiatives. There were no acquisitions, divestitures, or major restructuring activities disclosed in the quarter. The company’s dividend policy remained intact, with distributions declared earlier in the year, reflecting continued capital return to shareholders despite profit pressures. Management reaffirmed that its cash position and working capital are sufficient to meet operational needs and support strategic projects over the next 12 months. Overall, United-Guardian’s second-quarter results reflected a challenging sales environment in its largest product category but showed resilience in pharmaceuticals and medical lubricants. While near-term performance will depend heavily on a recovery in cosmetic ingredient demand, the company’s longer-term growth prospects may be supported by targeted expansion of its flagship pharmaceutical product into more formularies. The next few quarters will likely determine whether these strategic initiatives can offset category-specific weaknesses and restore top-line growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United-Guardian, Inc. (UG): Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research